Study to Evaluate Safety and Activity of Inhaled TRL1068 in Healthy Volunteers
Part of paid clinical trials in Lincoln, Nebraska.
- Sponsor
- Trellis Bioscience LLC
- Study ID
- NCT07644195
- Phase
- PHASE1
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Healthy Volunteer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Accepted
Interventions
- TRL1068, a human monoclonal antibody — DRUGThe IP will be in a solution for inhalation at a nominal concentration of 20 mg/mL. The IP will be reconstituted with a formulation buffer to 10 mg/mL/PS20 0.055% and dosed at a fixed dose of 60 mg per dose (volume of 6 mL) to full completion. Placebo will be normal saline. This study will use a marketed nebulizer device, the Aerogen Solo™, which is designed to generate an aerosol to achieve effective levels of TRL1068 in distal airways.
Study Details
This study in healthy volunteers will provide a basis for evaluation of inhaled TRL1068 as a first in human study, specifically, important safety, tolerability, and pharmacokinetic data.
Key Dates
- Start date
- Oct 31, 2026
- Status verified
- Jun 2026
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 14 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Single DoseRandomized 5:2 (TRL1068:placebo) via inhalation. Administered once on Day 1.
- Experimental: Multiple DoseRandomized 5:2 (TRL1068:placebo) via inhalation. Administered four times, on Days 1, 3, 5, and 7.
Primary Outcome Measure
Incidence of abnormal physical exam findings [ Time Frame: 30 days ]
Central Contacts
- Anton (Tony) Leighton, MD650-838-1400
- Adriane Kisch-Hancock650-838-1400
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Celerion | Lincoln | Nebraska | 68502 | - |
Find similar trials in Lincoln, NE
By research site
Related Studies
- Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 TabletsPHASE1 · Recruiting · Nurix Therapeutics, Inc. · Lincoln, Nebraska
- Safety and Tolerability Trial of Psilocybin in Healthy Older AdultsPHASE1 · Recruiting · University of Colorado, Denver · San Francisco, California
- Studies of Blood Flow to the Brain During ThoughtRecruiting · National Institute of Mental Health (NIMH) · Bethesda, Maryland
- Screening for Hematology Branch ProtocolsEnrolling By Invitation · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland